Oronsky B, Caroen S, Reid T. What exactly is inflammation (and what is it not?). Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232314905.

Article  PubMed  PubMed Central  Google Scholar 

Kelley N, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20133328.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Nunez G. The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci. 2023;48(4):331–44.

Article  CAS  PubMed  Google Scholar 

Kadowaki A, Quintana FJ. The NLRP3 inflammasome in progressive multiple sclerosis. Brain. 2020;143(5):1286–8.

Article  PubMed  PubMed Central  Google Scholar 

He W, et al. The role of NLRP3 inflammasome in sepsis: a potential therapeutic target. Int Immunopharmacol. 2023;115:109697.

Article  CAS  PubMed  Google Scholar 

Dixon KO, et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature. 2021;595(7865):101–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabatos CA, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102–10.

Article  CAS  PubMed  Google Scholar 

Dixon KO, Lahore GF, Kuchroo VK. Beyond T cell exhaustion: TIM-3 regulation of myeloid cells. Sci Immunol. 2024;9(93):eadf2223.

Article  CAS  PubMed  Google Scholar 

Kearley J, McMillan SJ, Lloyd CM. Th2-driven, allergen-induced airway inflammation is reduced after treatment with anti-Tim-3 antibody in vivo. J Exp Med. 2007;204(6):1289–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, et al. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol. 2008;180(7):4409–14.

Article  CAS  PubMed  Google Scholar 

Lee J, et al. Expression of human TIM-3 and its correlation with disease activity in rheumatoid arthritis. Scand J Rheumatol. 2011;40(5):334–40.

Article  CAS  PubMed  Google Scholar 

Sakuishi K, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, et al. Negative regulation of Nod-like receptor protein 3 inflammasome activation by T cell Ig mucin-3 protects against peritonitis. Immunology. 2018;153(1):71–83.

Article  CAS  PubMed  Google Scholar 

Schweigert O, et al. Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by a disintegrin and metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine. Biochim Biophys Acta. 2014;1843(2):275–87.

Article  CAS  PubMed  Google Scholar 

Hansen JA, et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(9):1323–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren F, et al. Plasma soluble Tim-3 emerges as an inhibitor in sepsis: sepsis contrary to membrane Tim-3 on monocytes. Tissue Antigens. 2015;86(5):325–32.

Article  CAS  PubMed  Google Scholar 

Ueland T, et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J Allergy Clin Immunol. 2021;147(1):92–8.

Article  CAS  PubMed  Google Scholar 

Zhao D, et al. Elevated soluble Tim-3 correlates with disease activity of systemic lupus erythematosus. Autoimmunity. 2021;54(2):97–103.

Article  CAS  PubMed  Google Scholar 

Bailly C, et al. Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. Biochem Pharmacol. 2023;209:115445.

Article  CAS  PubMed  Google Scholar 

Andrews LP, et al. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity. Cell. 2024;187(16):4355-4372.e22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cillo AR, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024;187(16):4373-4388.e15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ngiow SF, et al. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell. 2024;187(16):4336-4354.e19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong B, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216(4):982–1000.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gorgulho J, et al. Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies. Br J Cancer. 2024;130(6):1013–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie C, et al. Soluble B7–H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-kappaB pathway. Sci Rep. 2016;6:27528.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haile ST, et al. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013;191(5):2829–36.

Article  CAS  PubMed  Google Scholar 

Chen C, et al. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. Cell Rep Med. 2024;5(8):101686.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang L, et al. Tim-3 relieves experimental autoimmune encephalomyelitis by suppressing MHC-II. Front Immunol. 2021;12:770402.

Article  CAS  PubMed  Google Scholar 

Picon C, et al. Identification of the immunological changes appearing in the CSF during the early immunosenescence process occurring in multiple sclerosis. Front Immunol. 2021;12:685139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138–50.

Article  CAS  PubMed  Google Scholar